867256-77-7

Usage

Uses

Used in Pharmaceutical Synthesis:
4-CarBoxy-3-fluoroBenzeneBoronicacid,pinacolester is used as a key building block for the synthesis of various pharmaceuticals. Its unique structure allows for the creation of complex organic molecules with potential therapeutic applications.
Used in Organic Chemistry Research:
In the field of organic chemistry, 4-CarBoxy-3-fluoroBenzeneBoronicacid,pinacolester is utilized as a reagent in the development of new chemical reactions and processes. Its boronic acid and carboxylic acid functionalities, along with the presence of a fluorine atom, provide a platform for exploring novel synthetic pathways and methodologies.
Used in Material Science:
4-CarBoxy-3-fluoroBenzeneBoronicacid,pinacolester is employed as a precursor in the synthesis of advanced materials with specific properties, such as those with enhanced thermal stability, electrical conductivity, or optical characteristics.
Used in Agrochemical Development:
In the agrochemical industry, 4-CarBoxy-3-fluoroBenzeneBoronicacid,pinacolester is used as an intermediate in the synthesis of active ingredients for pesticides and other crop protection products, contributing to the development of more effective and environmentally friendly solutions.
Each application leverages the unique properties of 4-CarBoxy-3-fluoroBenzeneBoronicacid,pinacolester, such as its reactivity, structural diversity, and the ease of removal of the pinacol ester protecting group, to advance the respective fields.

InChI:InChI=1/C13H16BFO4/c1-12(2)13(3,4)19-14(18-12)8-5-6-9(11(16)17)10(15)7-8/h5-7H,1-4H3,(H,16,17)

Upstream product

• 120153-08-4 4-(dihydroxyboranyl)-2-fluorobenzoic acid 
• 76-09-5 2,3-dimethyl-2,3-butane diol 

Downstream Products

• 1205683-48-2 (2,6-dimethyl-morpholin-4-yl)-[2-fluoro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-methanone 
• 1492042-96-2 2-(cyclohexylamino)-2-oxo-1-phenylethyl-2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1492042-99-5 2-(cyclohexylamino)-2-oxo-1-(4-(trifluoromethyl)phenyl)ethyl-2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1492043-02-3 2-(cyclohexylamino)-1-(2-fluorophenyl)-2-oxoethyl-2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1492043-06-7 2-(cyclohexylamino)-1-(3-methoxyphenyl)-2-oxoethyl-2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1492043-09-0 2-(cyclohexylamino)-1-(2-methoxyphenyl)-2-oxoethyl-2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1492043-12-5 2-(cyclohexylamino)-2-oxo-1-(pyridin-3-yl)ethyl-2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 

Relevant academic research and scientific papers

GLUCOSE SENSITIVE INSULIN DERIVATIVES

The present invention relates to novel insulin derivatives and their use in the treatment or prevention of medical conditions relating to diabetes. The insulin derivatives are glucose sensitive and display glucose-sensitive albumin binding. The invention

HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases

NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

[1,2,4]Triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: (I) These compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection) and proliferative diseases.

HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases